# A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

> **NCT02974725** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 241 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Melanoma

## Interventions

- **DRUG:** LXH254
- **DRUG:** LTT462
- **DRUG:** Trametinib
- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT02974725
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-24
- **Primary completion:** 2024-04-24
- **Final completion:** 2024-04-24
- **Target enrollment:** 241 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02974725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02974725, "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02974725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*